ReviewCancer imaging : the official publication of the International Cancer Imaging Society2019
How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- A Framework for MRI Characterization of Intracranial Metastatic Disease.Radiology. Imaging cancer · 2026Review
- Differentiation Between Radiation Necrosis and True Tumour Progression After Radiotherapy to Intracranial Metastases.Journal of medical imaging and radiation oncology · 2025Review
- Dual-Tuned Coaxial-Transmission-Line RF Coils for HyperpolarizedIEEE transactions on bio-medical engineering · 2024Article
- Article
- [6,6'-NMR in biomedicine · 2023Article
- Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Deuterium Metabolic Imaging-Rediscovery of a Spectroscopic Tool.Metabolites · 2021Review
- The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technical advances in imaging are well demonstrated by MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography). Excellent anatomical detail and a lack of ionising radiation make MRI the standard of care for most neuroimaging indications, and advanced sequences are providing an ever-growing ability for lesion characterisation. PET utilising the tracer fluorine-18 fluorodeoxyglucose is widely used in oncology, while newer PET tracers are able to target a growing number of metabolic pathways and cell membrane receptors. The sequential use of these modalities harnesses the strengths of both, providing complementary diagnostic and therapeutic information.Here we outline the ways in which we use MRI and PET in a complementary manner to improve lesion characterisation in neuro-oncology. Most commonly, an abnormality is detected on either PET or MRI, and the addition of the other modality allows a more confident diagnosis and/or demonstrates additional lesions, guiding treatment decisions and, in some cases, obviating the need for biopsy. These modalities may also be combined to guide the treatment of intracranial masses for which the diagnosis is known, such as neuro-endocrine tumour metastases or meningiomas refractory to conventional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.